WASHINGTON UNIVERSITY SCHOOL OF

AT WASHINGTON UNIVERSITY MEDICAL CENTER

DIVISION OF RECEIVED BY LEMB RADIATION SAFETY Date Grig. Ta. **Action Compt** November 9, 1984

Bruce Mallett, Ph.D., Chief Regional Licensing Section Division of Fuel Cycle & Material Safety U.S. Nuclear Regulatory Commission 799 Roosevelt Road Glen Ellyn, Illinois 60137

Reference: USNRC License Numbers

24-00063-08 & 24-00063-10

Dear Dr. Mallett:

The purpose of this correspondence is to request the U.S. Nuclear Regulatory Commission to amend Condition 12 of the two Washington University Medical Center (St. Louis, Missouri) teletherapy licenses (24-00063-08 & 24-00063-10) to authorize Robert J. Myerson, M.D., and Robert R. Kuske, M.D., to use the licensed material in addition to the physicians who are certified by the American Board of Radiology in Radiology or Therapeutic Radiology and who have been approved by the licensee's Radiation Safety Committee. (The name of the institutional radiation committee has been recently changed to Radiation Safety Committee; previously, the name was the Radiation Hazards Committee).

Information regarding the training and experience of Drs. Kuske & Myerson as well as letters of recommendation from the institutions where they received their radiation oncology training are enclosed in duplicate.

A check in the amount of \$240 for the 2 amendments is also enclosed.

Singerely, Amount/Fee Category Type of Fee alma Date Check Rec'd .// John Eichling, Ph.D. Radiation Safety Officer Received By 4 Washington University & enclosures Affiliated Institutions

CONTROL NO. 77805

9120127 850828 PDR

Box 8131

JE:fiw

510 S. Kingshighway

St. Louis, Missouri 63110

(314) 362-2988

RECEIVED

NOV 15 1984

REGION III

140V 15 90V

PRECEPTOR STATEMENT

Supplement 8 must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS FULL NAME Robert J. Myerson, M.D. STREET ADDRESS 4511 Forest Park Blvd., Suite 311 CITY I STATE | ZIP CODE St. Louis, MO 63108

KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF:

- 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment,

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISCTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	(Additional information or comments may be submitted in duplicate on separate sheets.)
	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
1-131	LIVER FUNCTION STUDIES	1- 1	
or 1-125	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
GITIER			
1-125	DEJECTION OF THROMBOSIS		
1-131	THYROID IMAGING		
F-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
	BRAIN IMAGING		
	CARDIAC IMAGING	EL HILL	
	THYROID IMAGING	1 1 1 1 1 1 1 1	
	SALIVARY GLAND IMAGING		
Tc-99m	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNGIMAGING		
	BONE IMAGING		
OTHER			

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets,)
A	8	С	D
(Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
1-131	TREATMENT OF THYROID CARCINOMA		
1-131	TREATMENT OF HYPERTHYROIDISM		
Au-198	INTRACAVITARY TREATMENT	1	
Co-60 or	INTERSTITIAL TREATMENT		
Cs-137	INTRACAVITARY TREATMENT	10	
I-125 or Ir-192	INTERSTITIAL TREATMENT	17	
Co-60 or C≽137	TELETHERAPY TREATMENT	50	
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

100	THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:	6. PRECEPTOR'S SIGNATURE
	a NAME OF SUPERVISOR	Harry M. Dalvie.
	& NAME OF INSTITUTION Dept. ot Radiation	7. PRECEPTOR'S NAME (Please type or print)
	Therapy Hosp. Univ. of Pennsylvania	James M. Galvin
	3400 Spruce ST	8. DATE
5,	Philadelphia, PA 19104 MATERIALS LICENSE NUMBER(S)	Sept 27,1984
	37-118-07 Exp. Date Aug 88	

NRC FORM 313M SUPPLEMENT B (9-81)

CONTROL NO. 77805

GPO 890-918

TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE Pennsylvania; Missouri

Robert J. Myerson

	3. CERTIFICATION	
SPECIALTY BOARD	CATEGORY B	MONTH AND YEAR CERTIFIED
Board Eligible Radiation Therapy		

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

		TYPE AND LENGT	H OF TRAINING
FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING	LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours)
a. RADIATION PHYSICS AND INSTRUMENTATION	Department of Radiation Therapy Hospital of the Univ. of PA 7/81-6/84	40	40
b. RADIATION PROTECTION	n n	20	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	" "	20	
d. RADIATION BIOLOGY	" "	20	
e. RADIOPHARMACEUTICAL CHEMISTRY	n n	10	

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIE	NCE WAS GAINED	DURATION	FEXPERIENCE	TYPE OF USE
Ir ¹⁹²	75 mg Radium Equivalents	Hospital of t Pennsylvania Oncologic Hos	& American	7/81 -	- 6/84	Implants for breast, head & neck, and anal carcinoma
1125	35 m Ci			"	"	Prostate Implan
Cs ¹³⁷	80 mg Fadium Equivalents	"	n	"	" -	Gynecologic Intracavitary

NRC FORM 313M Supplement A (9-81)

Treatment



UNIVERSITY of PENNSYLVANIA

SCHOOL OF MEDICINE

DEPARTMENTS OF RADIATION THERAPY
University of Pennsylvania
and
The Fox Chase Cancer Center

Physics Section
Peter Bloch, Ph. D. - Director
James M. Galvin, D.Sc.
Ronald D. Larsen, Ph.D.
James C.H. Chu, Ph.D.
Marc R. Sontag, Ph.D.
Martin D. Altschuler, Ph.D.
V.K. Prasanna Kumar, Ph.D.

Mailing Address:

Hospital of the University of Pennsylvania 3400 Spruce Street Philadelphia, Pennsylvania 19104

(215) 662-6204/3084

22nd October 1984

John Eichling, Ph.D.
Radiation Safety Officer
Mallinckrodt Institute of Radiology
St. Louis, Missouri

Dear Dr. Eichling:

I am writing at this time to recommend Dr. Robert Myerson as a user of radioactive materials at your institution. It is my opinion that Bob's training in the use of sealed sources for therapeutic purposes is sufficient to allow him to carry out these duties independently. I would rate Bob's understanding of the clinical aspects of brachytherapy as superior. Also, evidently due to his strong background in physics, his grasp of radiation safety is excellent. I would recommend him without hesitation.

Please let me know if any additional information is needed.

Sincerely,

James M. Galvin, D.Sc.

James M. Calvin

JMG/amr cc:

PRECEPTOR STATEMENT

Supplement 8 must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1.	APPLICANT PHYSICIAN'S NAME AND ADDRESS					
	FULL	NAME		W.		
		Robert R. Kuske	e, M.D.			
	STREET ADDRESS					
		4554 Laclede Av	ve., #304			
	CITY		STATE	ZIP CODE		
		St. Louis	MO	63108		

KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF:

- Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	(Additional information or comments may be submitted in duplicate on separate sheets.)
	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
I-131	LIVER FUNCTION STUDIES		
or I-125	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
1-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	THE RESERVE OF THE RE	
P-32	EYE TUMOR LOCALIZATION		B. H. 목표를 만난번째다.
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
Tc-99m	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		
OTHER			

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	(Additional information or comments may be submitted in duplicate on separate sheets,)
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	2	BONE METASTASES FROM PROSTATE CANCER
P-32 (Colloidal)	INTRACAVITARY TREATMENT	3	OVARY CANCER
1.121	TREATMENT OF THYROID CARCINOMA	1	
1-131	TREATMENT OF HYPERTHYROIDISM		
Au-198	ÎNTRACAVITARY TREATMENT		
Co-60	INTERSTITIAL TREATMENT		
or Cs-137	INTRACAVITARY TREATMENT	39	CANCER CERUIY AND ENDOMETRIUM
I-125 or Ir-192	INTERSTITIAL TREATMENT	3	BREAST CANCER
Co-60 or Cs-137	TELETHERAPY TREATMENT	360	VARIOUS TUMBES
Sr-90	TREATMENT OF EYE DISEASE	3	Preryevay
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
To-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

JULY 1 1981 - JUNE 30 1984

135 HRS.

THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:	6. PRECEPTOR'S SIGNATURE	
Bernard S. Aron, M.D., FACR	Brus acm mb, FACR.	
Division of Radiation Oncology University Hospital c. MAILING ADDRESS 234 Goodman Street	7. PRECEPTOR'S NAME (Please type or print) Bernard S. Aron, M.D., FACR	
Cincinnati, Ohio 45267-0757	8. DATE 9/12/84	
d CITY		

NRC FORM 313M SUPPLEMENT B (9-81)

NRC FORM 313M SUPPLEMENT A

U.S. NUCLEAR REGULATORY COMMISSION

(9-81)

TRAINING AND EXPERIENCE

	AUTHORIZ	ZED USER OR RADIATION S	AFETY OFFICER	2			
1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER ROBERT ROYMOND KUSEE TR M.D. 3. CERTIFICATION					2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE OHIO 4 MISSOURI		
	SPECIALTY BOARD		CATEGORY		EAR CERTIFIED		
Therap	entic Rudislygy			BOOK J E	ligible 1 SPRING '95)		
	4. TRAINING	RECEIVED IN BASIC RADIOISOT	OPE HANDLING T	ECHNIQUES			
				TYPE AND LENG	GTH OF TRAINING		
	FIELD OF TRAINING	LOCATION AND DATE	(S) OF TRAINING	LECTURE/ LABORATORY COURSES (Hours)	SUPERVISED LABORATORY EXPERIENCE (Hours)		
1 700	DIATION PHYSICS AND TRUMENTATION	UNIVERITY OF CIN	The second secon	100	100		
b. RAC	DIATION PROTECTION	UNIU, OF CIME	NATI	40	16		
TH	THEMATICS PERTAINING E USE AND MEASUREMEN RADIOACTIVITY		CINNAT!	100	100		
d. RAI	DIATION BIOLOGY	UNIV. OF C	NCINARTI	(04	. (50		
	DIOPHARMACEUTICAL EMISTRY	UNIV. OF CI	NLINNATI	10	10		
	5. EXPERIENCE	WITH RADIATION. (Actual use of	Radioisotopes or Eq	uivalent Experien			
ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED			TYPE OF USE		
(060 A0148 Roma Trus For	2000 Cit 50 mCi 200 7 hCg	UNIV & CINCHNATI	6/31 -	6/84	lt, Treatment		

University of Cincinnati Medical Center



College of Medicine

Division of Radiation Oncology University of Cincinnati Hospital

Mail Location 757 234 Goodman Street Cincinnati, Ohio 45267 Phone (513) 872-4775

September 17, 1984

John Eichling, M.D.
Radiation Safety
X-Ray
Mallinckrodt Inst. of Rdiology
510 S. Kingshighway
St. Louis, MO 63110

RE: Robert R. Kuske, M.D.

Dear Dr. Eichling:

Dr. Kuske completed a three-year residency program in Radiation Oncology in June, 1984. This is to advise that Dr. Kuske is qualified in the use of radioiosotopes.

Sincerely,

Bernard S. Aron, M.D., FACR

Director, Division of Radiation Oncology

mm

BSA/jr

encl.

CONTROL NO. 77805